BMS 986016

Drug Profile

BMS 986016

Alternative Names: Anti-LAG-3; Anti-LAG-3 monoclonal antibody; Anti-LAG-3 monoclonal antibody - Bristol-Myers Squibb; Anti-lymphocyte activation gene 3 monoclonal antibody; BMS-986016

Latest Information Update: 16 Feb 2017

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Ono Pharmaceutical
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD223 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gastric cancer; Renal cell carcinoma
  • Phase I Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Glioblastoma; Hodgkin's disease; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 01 Jan 2017 Phase-II clinical trials in Renal cell carcinoma (Combination therapy, Late-stage disease) in USA (IV) (NCT02996110)
  • 16 Dec 2016 Bristol-Myers Squibb plans the phase II FRACTION-RCC trial for Renal cell carcinoma (Combination therapy, Late-stage disease) in USA, Israel, Italy and Canada (IV) (NCT02996110)
  • 01 Nov 2016 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater) in Japan (IV) (NCT02966548)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top